Why the study?
What is the role of pregnancy-associated plasma protein-A (PAPP-A) as a biomarker for diagnosis and prognosis in patients with acute coronary syndrome?
What is the role of pregnancy-associated plasma protein-A (PAPP-A) as a biomarker for diagnosis and prognosis in patients with acute coronary syndrome?
This review highlights the potential and challenges of using PAPP-A as a biomarker for vulnerable plaque and acute coronary syndrome.
For more than a decade, pregnancy-associated plasma protein-A (PAPP-A) has been examined for its relation to acute coronary syndrome (ACS) and the vulnerable plaque. This review summarizes the current knowledge of plasma PAPP-A in relation to nonpregnant individuals focusing on patients with ACS, discusses its use as a possible biomarker for diagnosis and prognosis in ACS, briefly describes the challenges in different assay technologies and describes the effect of heparin administration on PAPP-A concentrations in plasma.
No takes yet. Share an insight, caveat, or question.
Jespersen et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: